SCYNEXIS, Inc. SCYX

SCYNEXIS, Inc. announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective Sept. 18, 2026. Burke, a nephrology-focused biopharma veteran with 30+ years in drug development, has led R&D at Akebia Therapeutics since 2019 and served as Chief Medical Officer since 2021, guiding programs including vadadustat and ferric citrate. He previously founded Abfero Pharmaceuticals and held senior roles at Proteon Therapeutics and Genzyme. The addition comes as SCYNEXIS advances SCY-770 toward Phase 2 for ADPKD, an AMPK activator with FDA Orphan Drug designation. Chairman Guy Macdonald called Burke’s expertise a strategic asset during a transformative year after acquiring SCY-770. Burke noted SCYNEXIS’ antifungal platform, together with SCY-770, could position the company as a leader in therapies for severe rare diseases. Board-level expertise in kidney-disease development could meaningfully influence SCY-770 strategy and investor sentiment as the asset advances, but it does not yet redefine the company’s trajectory.

SCYNEXIS reported second quarter 2026 financial results and issued a corporate update. Quarterly earnings releases supply performance data that can shift near-term valuation and sentiment.

SCYNEXIS initiates Phase 1 study of SCY-770, a novel AMPK activator, for treatment of autosomal dominant polycystic kidney disease. Phase 1 start advances pipeline in new indication with moderate effects on operations and sentiment.

SCYNEXIS, Inc. (SCYX) reported first quarter 2026 financial results and provided a corporate update. Quarterly financial results and corporate updates often drive significant changes in stock price and investor sentiment.

SCYNEXIS secures $40 million through private placement and completes acquisition of PXL-770, a novel treatment for kidney disease. $40 million funding infusion and PXL-770 acquisition represent major strategic expansion into kidney disease, enhancing pipeline and financial runway for SCYX.

SCYNEXIS, Inc. (SCYX) announces a $40.0 million private placement to fund ongoing operations and clinical development. $40 million private placement provides substantial non-dilutive capital infusion critical for biotech survival and growth, significantly impacting financial runway and stock trajectory.

SCYNEXIS, Inc. (SCYX) completes transformative acquisition of PXL-770, an innovative, highly selective direct AMPK activator for treating autosomal dominant polycystic kidney disease (ADPKD). Transformative acquisition of PXL-770 expands SCYX pipeline into ADPKD treatment, representing a major strategic move with significant potential to alter trajectory and investor sentiment.

SCYNEXIS, Inc. (SCYX) announced dosing of first participants in Phase 1 clinical trial of SCY-247 antifungal therapy. Phase 1 trial initiation for SCY-247 advances SCYX's antifungal pipeline moderately, potentially boosting investor sentiment amid early-stage risks.

SCYNEXIS, Inc. (SCYX) reported full year 2025 financial results and provided a corporate update. Full-year financial results and corporate updates significantly affect investor sentiment and stock trajectory.

SCYNEXIS, Inc. (SCYX) released its Q4 earnings snapshot, detailing financial results for the quarter. Q4 earnings snapshots reveal key financial metrics that moderately influence SCYX's stock performance and investor outlook.

SCYNEXIS, Inc. (SCYX) announces first participants dosed in Phase 1 single ascending dose and multiple ascending dose trial of intravenous SCY-247. Advancing to first dosing in Phase 1 trial of SCY-247 progresses SCYNEXIS's antifungal pipeline with moderate potential to affect investor sentiment and competitive positioning.

SCYNEXIS, Inc. announced presentations at the inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI) showcasing the strong antifungal activity of its second-generation drug, SCY-247, against drug-resistant fungi. The findings highlight the potential of SCY-247 to address significant challenges in treating fungal infections, particularly those resistant to existing therapies. The presentation of SCY-247's efficacy against drug-resistant fungi could significantly enhance SCYNEXIS's competitive position and market sentiment.

SCYNEXIS, Inc. has received FDA Qualified Infectious Disease Product (QIDP) and Fast Track designations for its investigational drug SCY-247, aimed at treating invasive fungal infections. These designations are intended to expedite the development and review process, potentially allowing for faster access to the market. The company is focused on addressing significant unmet medical needs in the treatment of serious fungal infections. The FDA designations are likely to significantly enhance SCYNEXIS's development timeline and market positioning for SCY-247.

SCYNEXIS, Inc. has been granted a 180-day extension by Nasdaq to regain compliance with the minimum bid price requirement. This extension allows the company additional time to meet the necessary stock price criteria to avoid delisting. The extension is crucial for SCYNEXIS as it continues to work on its business strategies and product developments. The extension provides SCYNEXIS with critical time to stabilize its stock price, which may influence investor sentiment and operational focus.

SCYNEXIS, Inc. has successfully transferred the New Drug Application for BREXAFEMME® to GlaxoSmithKline (GSK). This transfer marks a significant step in the collaboration between the two companies, as GSK will now take over the regulatory responsibilities for the drug. BREXAFEMME® is an antifungal treatment aimed at addressing specific infections, and this move is expected to enhance its market potential under GSK's established infrastructure. The transfer of the New Drug Application to GSK is a significant strategic move that could enhance the market positioning and future performance of SCYNEXIS.

SCYNEXIS, Inc. announced federal funding for a collaboration between Hackensack Meridian CDI and Johns Hopkins researchers aimed at developing new therapeutics, including novel fungicides, to combat resistant fungal infections. This initiative highlights the growing need for innovative solutions in the face of increasing antifungal resistance. The collaboration could lead to significant advancements in therapeutic options for resistant fungal infections, impacting SCYNEXIS's strategic positioning and market potential.

SCYNEXIS, Inc. is facing concerns regarding its cash burn rate, which could impact its financial stability and operational capabilities. The company has been experiencing significant losses, raising questions about its ability to sustain operations without additional funding. Investors are advised to monitor the situation closely as the cash burn could affect future growth and strategic initiatives. The cash burn situation may moderately influence SCYNEXIS' financial performance and operational strategy.

SCYNEXIS, Inc. reported its Q3 earnings, highlighting key financial metrics and operational updates. The company continues to focus on its antifungal drug development, with ongoing clinical trials and regulatory efforts. Despite challenges in the market, SCYNEXIS remains committed to advancing its product pipeline and addressing unmet medical needs in the antifungal space. The earnings report reflects ongoing developments in product innovation and market positioning, which may moderately influence financial performance.

SCYNEXIS, Inc. (SCYX) reported its financial results for the third quarter of 2025, highlighting key metrics and developments in its corporate strategy. The company continues to focus on advancing its product pipeline and addressing market needs. Financial performance showed trends that may influence future operations and investor sentiment. Financial results and corporate updates indicate moderate influence on SCYNEXIS's operational trajectory and market positioning.

SCYNEXIS, Inc. announced positive results from a Phase 1 clinical trial for its second-generation antifungal drug, SCY-247. The trial demonstrated favorable safety and pharmacokinetic profiles, indicating potential for effective treatment against fungal infections. The company aims to advance SCY-247 into further clinical trials, highlighting its commitment to addressing unmet medical needs in antifungal therapies. Positive Phase 1 results for SCY-247 could significantly enhance SCYNEXIS's product pipeline and market position in the antifungal sector.

SCYNEXIS, Inc. and GSK have resolved their disagreement regarding the restart of the Phase 3 MARIO Study. This resolution allows SCYNEXIS to proceed with the clinical trial, which is crucial for the development of its antifungal treatment, potentially impacting its market position and future growth. The resolution of the disagreement enables SCYNEXIS to advance a significant clinical trial, likely influencing its future performance and investor sentiment.

SCYNEXIS, Inc. announced positive Phase I clinical trial results for its antifungal drug SCY-247, which demonstrated favorable safety and tolerability profiles. The trial also showed promising pharmacokinetics and pharmacodynamics, indicating potential effectiveness against invasive fungal infections. These results support further development of SCY-247, with plans for upcoming Phase II trials to evaluate its efficacy in a broader patient population. Positive Phase I data for SCY-247 could significantly enhance SCYNEXIS's product pipeline and market position in the antifungal space.

SCYNEXIS, Inc. announced positive results from a Phase 1 study of its second-generation antifungal drug, Fungerp (SCY-247). The study included both single ascending dose and multiple ascending dose cohorts, demonstrating a favorable safety profile and pharmacokinetics. These findings support the continued development of SCY-247 for treating fungal infections, with plans for further clinical trials to assess its efficacy. Positive Phase 1 results for SCY-247 indicate significant potential for future product development and market positioning.

SCYNEXIS, Inc. announced multiple presentations showcasing data from its second-generation antifungal drug, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12). These presentations highlight the drug's potential in treating fungal infections, emphasizing its innovative approach and efficacy. The company aims to leverage this data to enhance its market position and attract interest from investors and healthcare professionals. The presentations at TIMM-12 could significantly influence SCYNEXIS's market positioning and investor sentiment regarding SCY-247's potential in the antifungal market.

SCYNEXIS, Inc. reported its second quarter 2025 earnings, surpassing analysts' expectations. The company highlighted strong revenue growth driven by increased demand for its antifungal treatments. Management expressed optimism about future product launches and ongoing clinical trials, which are expected to enhance market presence. The positive earnings report has led to a favorable response from investors, reflecting confidence in SCYNEXIS's strategic direction and operational performance. The earnings beat indicates significant operational progress and potential for future growth, impacting investor sentiment positively.

SCYNEXIS, Inc. reported its Q2 earnings, highlighting a revenue of $3.5 million, which reflects a significant increase compared to the previous year. The company continues to focus on its antifungal drug, Brexafemme, which has shown promising sales growth. Additionally, SCYNEXIS is advancing its clinical trials and expanding its market presence. The overall financial outlook remains cautiously optimistic as the company navigates challenges in the competitive landscape. The earnings report indicates moderate growth and ongoing clinical advancements, which may influence financial performance but are balanced by competitive challenges.

SCYNEXIS, Inc. (SCYX) reported its financial results for the second quarter of 2025, highlighting key metrics and developments in its corporate strategy. The company provided updates on its ongoing clinical trials and product pipeline, emphasizing progress in its antifungal treatments. Financial performance showed fluctuations in revenue and expenses, reflecting the company's investment in research and development. Management expressed optimism about future growth and potential market opportunities, while addressing challenges faced in the competitive landscape. Ongoing clinical trials and product pipeline developments may moderately influence SCYNEXIS's financial performance and market positioning.

SCYNEXIS, Inc. has resumed patient dosing in its Phase III MARIO trial for Brexafemme after the FDA lifted a 19-month clinical hold due to contamination concerns. The hold was removed following the production of new drug batches at a different facility. Patient enrollment has reached 25% of the 220-participant goal. SCYNEXIS received a $10 million milestone payment from GSK after the first new patient was dosed, although tensions exist between the partners over further payments and trial responsibilities. Brexafemme, previously recalled in 2023, has FDA approval for treating VVC, with projected global revenue potentially reaching $139 million by 2031 if development is successful. The resumption of the Phase III trial and lifting of the FDA hold are significant developments that could greatly influence SCYNEXIS's future performance and market sentiment.

Scynexis has resumed dosing in its Phase III MARIO study for Brexafemme (ibrexafungerp) after a 19-month FDA clinical hold due to cross-contamination concerns. The hold was lifted following the manufacture of new clinical supplies at a different site. The study aims to evaluate Brexafemme as a step-down antifungal therapy for invasive candidiasis. Scynexis has enrolled about 25% of its target of 220 patients. The company is also navigating a dispute with GSK regarding milestone payments tied to the study's progress. Scynexis reported $3.7 million in revenue for 2024, primarily from its licensing agreement with GSK, and anticipates significant future sales depending on the study's outcome. The resumption of the MARIO study and the ongoing partnership with GSK are critical for Scynexis's future revenue and market positioning.

SCYNEXIS, Inc. has resumed patient dosing in the Phase 3 MARIO study after the FDA lifted a clinical hold. This study investigates oral ibrexafungerp as a potential treatment for invasive candidiasis. The resumption triggers a $10 million milestone payment from GSK, with an additional $20 million due in six months, although GSK disputes these payments. The study aims to provide a non-azole oral therapy option for patients, addressing a significant unmet need in treating drug-resistant infections. SCYNEXIS has already enrolled about 25% of the projected patients. Resuming the MARIO study and potential milestone payments from GSK could significantly impact SCYNEXIS's financial performance and market position.